This site is intended for healthcare professionals
Drug news

Phase III study results for Tecentriq + Cotellic + Zelboraf for previously untreated BRAF V600 mutation-positive advanced melanoma.-Genentech/Roche

Read time: 1 mins
Last updated:14th Dec 2019
Published:14th Dec 2019
Source: Pharmawand
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest